We further demonstrated the potential utility of a combination of TGFβ1 and CTGF as novel, minimally invasive molecular therapeutic agents for the biological treatment of degenerative disc disease (Fig. 8). Here, TGFB1 is linked to intervertebral disk degenerative disorder.